MedTrace Logo

MRI Gadopiclenol Enhanced Imaging of CNS Tumors

NCT06127810 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-02-04

No results posted yet for this study

Summary

The purpose of this pilot study is to compare a standard of care MRI scan to a non-standard of care MR imaging with portable (0.064 Tesla) MRI following the administration of non-SOC contrast called Gadopiclenol on 10 subjects with known brain tumors.

Participants will be randomized to receive either standard MRI or portable MRI first following contrast injection

Conditions

  • Image

Interventions

DEVICE

CE MRI on 0.064T Scanner

Pt will undergo contrast enhanced images using Gadopiclenol on Hyperfine MRI

DRUG

Gadopiclenol

Subjects will receive Gadopiclenol instead of standard of care contrast

Sponsors & Collaborators

  • Guerbet

    collaborator INDUSTRY

  • Medical University of South Carolina

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-30
Primary Completion
2024-12-30
Completion
2024-12-30
FDA Drug
Yes
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06127810 on ClinicalTrials.gov